The study further demonstrated that TRIM59 promotes degradation of tumor suppressor proteins RB1 and p53, which leads to increased SRY-box Transcription Factor 2 (SOX2) expression and drives neuroendocrine differentiation in prostate cancer [125]. The gene discussed is TP53; the disease is prostate cancer.